Designed as an Fc‐silent monoclonal antibody with anti‐CD16 (scFv) at the ends of the heavy chain, it effectively triggers ADCC in AML cell lines and blocks IL‐3R signalling, currently being tested in a Phase I trial with AML patients.64, 65. The gene discussed is FCGR3A; the disease is acute myeloid leukemia.